ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,413.935
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,808.93
-0.41%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. Medincell SA (MEDCL) Share Price

MEDCL Medincell SA

14.20
0.50 (3.65%)
17 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Medincell SA EU:MEDCL Euronext Ordinary Share FR0004065605 
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.50 3.65 14.20 14.02 14.28 14.20 13.54 13.54 119,450 15:40:00   
 Type  Size  Price  Time  Units 
  124 14.20 15:35:16 EUR
 
Recent News
DateTimeSource
HeadlineMore MEDCL News
14/05/202417:00BWMedincell fait le point sur l’essai clinique de phase 3 de mdc-CWM
14/05/202417:00BWMedincell Provides Update on Phase 3 mdc-CWM Clinical Trial
13/05/202417:25BWMedincell tiendra une vidéoconférence le mercredi 15 mai 2024 à 10h30 pour commenter ses actualités récentes, ses perspectives et ses activités R&D
13/05/202417:25BWMedincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities
10/05/202417:00BWMedincell : Information mensuelle relative au nombre d’actions composant le capital social et au nombre total des droits de vote
08/05/202411:30BWTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
08/05/202411:30BWTeva et Medincell annoncent des résultats d'efficacité positifs pour l’essai de phase 3 SOLARIS de TEV-‘749 (olanzapine / mdc-TJK), injection sous-cutanée à action prolongée mensuelle pour les adultes atteints de schizophrénie
Period
Draw mode
Data Downloads for MEDCL

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Medincell SA Articles